

Company Overview

PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed's diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its five lead technologies provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoGuard™/EsoCheck™), vascular access (PortIO™), pediatric ear infections (DisappEAR™) and medical infusions (NextFlo™). The company is also developing innovative products in other areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers.

PAVmed Closes \$13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Jan 8 2021, 10:53 AM EST

PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules

Jan 6 2021, 9:29 AM EST

PAVmed Closes Additional \$8.1 Million Common Stock Registered Direct Offering

Dec 22 2020, 12:04 PM EST

Stock Overview

Symbol	PAVM
Exchange	Nasdaq
Market Cap	144.53m
Last Price	\$2.01
52-Week Range	\$1.30 - \$3.46

01/15/2021 04:00 PM EST

Investor Relations

Mike Havrilla
Director of Investor Relations
T: 814-241-4138
JMH@PAVmed.com

Management Team

Lishan Aklog, MD

Chairman & Chief Executive Officer

Dennis McGrath

President & Chief Financial Officer

Brian deGuzman, MD

Chief Medical Officer

Shaun O'Neil, MBA

Chief Commercial Officer

PAVmed Inc.

One Grand Central Place
Suite 4600
New York, NY 10165

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.